AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
ACIU Stock Rallies 16.3% in a Week: Here's What You Need to Know
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
AC Immune (ACIU) Upgraded to Buy: Here's Why
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is AC Immune (ACIU) Outperforming Other Medical Stocks This Year?
Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.06 per share a year ago.
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.25 per share a year ago.
AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
